Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...

Specialty pharmacies and online companies were selling the off-brand copies while there was a shortage of Zepbound and Mounjaro.

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

Health-care companies fell amid ongoing concerns about a backlash against the industry. The SPDR Select Sector Health Care exchange-traded fund, which tracks the health-care industry group of the S&P ...

They’re next. And one last prediction. The mass market weight loss fad hyping GLP-1 drugs (Wegovy, Ozempic, Mounjaro, Zepbound) will implode. These drugs are now readily available, less expensive, and ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 480.21% and ...